Nifty
:
11604.10
Sensex
:
39058.83
15.75 (0.14%)
94.99 (0.24%)
Nifty
Sensex
:
:
11604.10
39058.83
15.75 (0.14%)
94.99 (0.24%)

Lincoln Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

Rating :
54/99

BSE: 531633 | NSE: LINCOLN

NSE BSE
156.40
23-Oct-2019
  • Open
  • High
  • Low
  • Previous Close
  •  163.85
  •  164.85
  •  155.35
  •  159.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  31133
  •  49.87
  •  275.90
  •  124.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 312.10
  • 7.05
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 338.13
  • 0.96%
  • 1.13

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 0%
  • 0%
  • 0%
  • FII
  • DII
  • Others
  • 0%
  • 0%
  • 0%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.41
  • 6.60
  • 0.54

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.67
  • 21.30
  • 7.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.09
  • 26.55
  • 20.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.28
  • 11.71
  • 12.70

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.35
  • 1.82
  • 1.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.91
  • 7.62
  • 7.94

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
96.81
99.82
-3.02%
79.32
67.13
18.16%
84.44
80.18
5.31%
102.60
89.65
14.45%
Expenses
77.76
76.53
1.61%
68.13
57.48
18.53%
70.83
64.03
10.62%
83.52
74.22
12.53%
EBITDA
19.05
23.30
-18.24%
11.19
9.65
15.96%
13.61
16.15
-15.73%
19.09
15.43
23.72%
EBIDTM
19.68%
23.34%
14.10%
14.38%
16.12%
20.14%
18.60%
17.21%
Other Income
1.29
2.30
-43.91%
-0.87
0.86
-
0.38
2.83
-86.57%
4.43
2.99
48.16%
Interest
0.65
1.33
-51.13%
0.79
0.94
-15.96%
0.71
1.37
-48.18%
1.75
1.50
16.67%
Depreciation
1.85
1.58
17.09%
1.65
1.53
7.84%
1.94
1.39
39.57%
1.51
1.81
-16.57%
PBT
17.85
22.68
-21.30%
7.88
8.04
-1.99%
11.34
16.22
-30.09%
20.26
15.12
33.99%
Tax
5.17
6.60
-21.67%
-0.59
1.21
-
2.20
4.64
-52.59%
5.25
3.80
38.16%
PAT
12.68
16.07
-21.10%
8.47
6.83
24.01%
9.14
11.58
-21.07%
15.01
11.32
32.60%
PATM
13.09%
16.10%
10.68%
10.17%
10.83%
14.45%
14.63%
12.63%
EPS
6.33
8.03
-21.17%
4.23
3.42
23.68%
4.57
5.79
-21.07%
7.50
5.65
32.74%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
363.17
366.18
360.61
360.26
400.15
266.07
210.49
194.70
187.58
176.51
124.34
Net Sales Growth
7.84%
1.54%
0.10%
-9.97%
50.39%
26.41%
8.11%
3.80%
6.27%
41.96%
 
Cost Of Goods Sold
174.09
135.68
156.44
202.90
254.64
161.12
123.72
113.96
111.61
105.50
62.40
Gross Profit
189.08
230.51
204.18
157.35
145.50
104.96
86.77
80.74
75.97
71.01
61.94
GP Margin
52.06%
62.95%
56.62%
43.68%
36.36%
39.45%
41.22%
41.47%
40.50%
40.23%
49.82%
Total Expenditure
300.24
298.96
308.30
313.52
359.62
240.47
190.42
179.22
174.08
166.98
113.18
Power & Fuel Cost
-
7.21
6.82
5.92
5.68
4.27
3.40
2.12
0.73
0.68
1.07
% Of Sales
-
1.97%
1.89%
1.64%
1.42%
1.60%
1.62%
1.09%
0.39%
0.39%
0.86%
Employee Cost
-
51.90
51.15
37.59
28.83
17.87
18.57
17.71
16.52
14.30
9.89
% Of Sales
-
14.17%
14.18%
10.43%
7.20%
6.72%
8.82%
9.10%
8.81%
8.10%
7.95%
Manufacturing Exp.
-
60.80
51.73
29.44
35.81
25.98
19.10
17.54
16.91
16.31
13.29
% Of Sales
-
16.60%
14.35%
8.17%
8.95%
9.76%
9.07%
9.01%
9.01%
9.24%
10.69%
General & Admin Exp.
-
20.72
17.50
14.78
20.34
18.86
15.07
13.25
13.36
7.77
13.61
% Of Sales
-
5.66%
4.85%
4.10%
5.08%
7.09%
7.16%
6.81%
7.12%
4.40%
10.95%
Selling & Distn. Exp.
-
20.02
21.24
19.91
10.10
9.42
8.42
13.22
13.66
22.18
12.84
% Of Sales
-
5.47%
5.89%
5.53%
2.52%
3.54%
4.00%
6.79%
7.28%
12.57%
10.33%
Miscellaneous Exp.
-
2.63
3.44
2.97
4.22
2.95
2.13
1.43
1.28
0.25
12.84
% Of Sales
-
0.72%
0.95%
0.82%
1.05%
1.11%
1.01%
0.73%
0.68%
0.14%
0.06%
EBITDA
62.94
67.22
52.31
46.74
40.53
25.60
20.07
15.48
13.50
9.53
11.16
EBITDA Margin
17.33%
18.36%
14.51%
12.97%
10.13%
9.62%
9.53%
7.95%
7.20%
5.40%
8.98%
Other Income
5.23
5.65
5.45
2.78
7.36
7.19
2.49
6.40
3.36
3.30
1.26
Interest
3.90
4.00
5.41
6.66
9.96
8.38
6.97
7.84
7.60
4.98
2.68
Depreciation
6.95
6.68
6.11
5.51
4.87
4.57
3.53
2.65
1.93
1.67
1.16
PBT
57.33
62.19
46.25
37.33
33.07
19.85
12.07
11.38
7.33
6.18
8.58
Tax
12.03
13.46
11.60
9.20
9.27
4.80
1.89
1.85
2.20
2.01
2.48
Tax Rate
20.98%
21.64%
25.08%
24.65%
28.03%
24.18%
15.66%
16.26%
30.01%
32.52%
28.90%
PAT
45.30
48.71
34.62
28.12
23.68
15.01
10.65
9.66
5.12
4.17
6.10
PAT before Minority Interest
45.26
48.74
34.65
28.13
23.80
15.04
10.18
9.53
5.13
4.17
6.10
Minority Interest
-0.04
-0.03
-0.03
-0.01
-0.12
-0.03
0.47
0.13
-0.01
0.00
0.00
PAT Margin
12.47%
13.30%
9.60%
7.81%
5.92%
5.64%
5.06%
4.96%
2.73%
2.36%
4.91%
PAT Growth
-1.09%
40.70%
23.12%
18.75%
57.76%
40.94%
10.25%
88.67%
22.78%
-31.64%
 
Unadjusted EPS
22.63
24.36
17.31
15.73
14.52
9.20
6.53
5.92
3.14
3.02
6.71

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
269.34
224.22
192.38
140.52
111.31
98.81
89.30
80.78
76.82
53.29
Share Capital
20.00
20.00
20.00
16.31
16.31
16.31
16.31
16.31
16.31
11.31
Total Reserves
249.34
204.22
172.38
116.65
95.00
82.50
72.99
64.47
60.50
41.98
Non-Current Liabilities
28.43
24.94
31.75
33.74
33.14
26.18
25.14
22.37
11.22
29.98
Secured Loans
1.69
6.93
12.38
23.62
15.27
16.20
14.41
12.33
2.54
25.61
Unsecured Loans
0.00
0.00
0.00
0.00
10.21
3.04
2.66
1.97
1.57
1.51
Long Term Provisions
17.49
7.19
9.98
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
99.63
113.48
99.42
100.34
114.47
131.05
118.26
104.86
77.24
27.67
Trade Payables
43.28
43.42
32.46
30.38
45.31
66.51
47.51
42.05
22.63
17.61
Other Current Liabilities
11.11
11.11
12.77
15.10
11.52
14.15
15.57
16.25
12.25
3.68
Short Term Borrowings
30.09
48.55
45.04
52.62
50.67
48.46
54.90
46.56
40.35
0.00
Short Term Provisions
15.16
10.41
9.15
2.24
6.97
1.92
0.27
0.00
2.01
6.38
Total Liabilities
397.76
362.97
323.85
274.79
261.85
259.75
236.88
212.31
165.28
110.94
Net Block
120.91
116.58
102.71
98.47
65.62
65.07
64.94
37.74
27.96
21.01
Gross Block
138.11
127.65
108.16
120.89
87.50
82.22
78.82
49.07
36.70
27.67
Accumulated Depreciation
17.21
11.08
5.45
22.42
21.88
17.15
13.89
11.33
8.74
6.66
Non Current Assets
161.92
136.08
134.27
127.83
80.64
110.69
113.67
90.73
45.38
22.14
Capital Work in Progress
2.10
0.29
6.63
2.73
2.55
2.37
2.37
13.51
4.14
1.13
Non Current Investment
0.09
0.09
0.09
0.01
0.01
0.41
0.41
0.41
0.00
0.00
Long Term Loans & Adv.
38.50
18.79
24.48
26.62
12.47
42.84
45.95
39.08
13.28
0.00
Other Non Current Assets
0.33
0.34
0.36
0.00
0.00
0.00
0.00
0.00
0.01
0.00
Current Assets
235.84
226.88
189.58
146.98
181.20
149.06
123.21
121.58
119.90
88.78
Current Investments
18.07
10.97
10.25
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
36.23
45.41
37.31
27.48
21.82
23.84
19.33
21.41
26.07
22.97
Sundry Debtors
122.47
109.44
90.67
80.53
119.01
89.04
74.79
65.37
40.08
31.38
Cash & Bank
7.58
14.59
11.68
12.66
11.51
10.45
15.15
16.86
13.14
13.49
Other Current Assets
51.50
1.29
0.66
0.05
28.86
25.73
13.94
17.94
40.61
20.94
Short Term Loans & Adv.
50.40
45.18
39.02
26.26
28.86
25.73
13.94
17.94
40.61
20.94
Net Current Assets
136.21
113.40
90.16
46.63
66.73
18.01
4.95
16.72
42.66
61.11
Total Assets
397.76
362.96
323.85
274.81
261.84
259.75
236.88
212.31
165.28
110.93

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
52.84
26.63
25.04
44.80
24.56
4.64
-15.60
11.87
-34.26
-10.55
PBT
62.19
46.25
37.33
33.07
19.85
12.07
9.53
5.13
8.24
8.58
Adjustment
9.30
11.64
10.70
13.75
10.68
12.75
8.96
14.32
7.27
1.21
Changes in Working Capital
-1.12
-22.00
-13.24
4.80
-2.50
-17.56
-32.36
-6.38
-48.08
-17.98
Cash after chg. in Working capital
70.38
35.88
34.79
51.62
28.02
7.26
-13.87
13.07
-32.58
-8.19
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-17.53
-9.25
-9.75
-6.82
-3.46
-2.62
-1.73
-1.20
-1.68
-1.85
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-18.19
-11.77
-25.48
-41.79
6.52
1.45
-16.27
-27.23
-10.89
-6.02
Net Fixed Assets
-11.52
-12.45
4.05
-29.04
-4.21
-0.95
-2.89
-4.61
-12.04
-6.33
Net Investments
-7.10
-2.72
-16.01
-7.34
-1.43
0.00
0.00
-11.16
0.00
0.00
Others
0.43
3.40
-13.52
-5.41
12.16
2.40
-13.38
-11.46
1.15
0.31
Cash from Financing Activity
-35.77
-11.41
0.30
-3.42
-32.04
-10.51
29.30
16.19
45.06
25.45
Net Cash Inflow / Outflow
-1.11
3.45
-0.14
-0.41
-0.96
-4.42
-2.57
0.82
-0.09
8.89
Opening Cash & Equivalents
6.57
3.12
3.26
3.75
4.82
9.39
11.97
11.53
11.62
4.60
Closing Cash & Equivalent
5.46
6.57
3.12
3.43
3.87
4.97
9.39
12.36
11.53
13.49

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
134.67
112.11
96.19
81.52
68.24
60.58
54.75
49.53
47.10
47.10
ROA
12.81%
10.09%
9.40%
8.87%
5.77%
4.10%
4.25%
2.72%
3.02%
6.64%
ROE
19.75%
16.63%
17.29%
19.49%
14.32%
10.83%
11.21%
6.51%
6.41%
13.76%
ROCE
22.50%
19.05%
18.51%
21.18%
15.91%
11.48%
12.21%
10.94%
10.97%
17.01%
Fixed Asset Turnover
2.76
3.07
3.19
3.90
3.20
2.67
3.10
4.45
5.60
5.05
Receivable days
115.58
100.99
85.52
89.69
139.97
139.16
128.96
100.92
72.36
78.28
Inventory Days
40.69
41.74
32.36
22.16
30.72
36.67
37.48
45.44
49.66
53.69
Payable days
56.75
47.62
37.21
40.22
92.31
115.76
98.21
75.46
45.35
48.51
Cash Conversion Cycle
99.51
95.11
80.67
71.63
78.37
60.06
68.23
70.90
76.67
83.46
Total Debt/Equity
0.12
0.27
0.34
0.59
0.69
0.69
0.85
0.86
0.60
0.51
Interest Cover
16.56
9.55
6.60
4.32
3.37
2.73
2.45
1.96
2.24
4.21

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Lincoln Pharmaceuticals receives patent for Diclofenac Rectal Spray
    22nd Oct 2019, 12:43 PM

    This Patent is valid for 20 years

    Read More
  • Lincoln Pharmaceuticals gets nod for scheme of amalgamation
    20th Sep 2019, 09:43 AM

    The Board of Directors of the Company at its meeting held on September 19, 2019 has approved the same

    Read More
  • Lincoln Pharma - Quarterly Results
    14th Aug 2019, 15:23 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.